Phase 2 trial shows significant improvements in Angelman
Neuren Pharmaceuticals reports significant improvements in Angelman syndrome treatment with NNZ-2591.
Neuren Pharmaceuticals
Angelman Syndrome
NNZ-2591
Clinical Trial Results
Stock Market News
Posted on: 09/08/2024
Read More